Valerio Therapeutics Société anonyme (LON:0NWK)

Market Cap	49.58M +476.3%
Revenue (ttm)	1.57M -3.1%
Net Income	-11.30M
EPS	-0.07
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,132
Average Volume	4,834
Open	0.1150
Previous Close	0.1095
Day's Range	0.1150 - 0.1150
52-Week Range	0.0498 - 0.3000
Beta	1.61
RSI	38.54
Earnings Date	Mar 30, 2026

About LON:0NWK

Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, designs and develops novel and first-in-class DNA-decoy therapies targeting proteins in tumors and inflammatory disease processes. The company develops developing VIO-01, which is in Phase 1/2 of the VIO-01 clinical study, a Pan-DDR DNA decoy targeting multiple proteins and repair pathways in preclinical development; and PlatON, generates DecoyTAC combining DNA decoy molecules capable of cell penetration with a linker+E3 ligand. It also develops V-body platform, a bis...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1997
• Employees: 25
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0NWK

Financial Performance

In 2024, LON:0NWK's revenue was 1.79 million, a decrease of -0.39% compared to the previous year's 1.80 million. Losses were -23.93 million, 17.6% more than in 2023.

Financial numbers in EUR